News

Publications

Erratum to: An exploratory randomized double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A. Orph J Rare Dis. 2016 Jul 7;11.92
˪ Attarian S, et al
July 7, 2016

Molecular changes in the postmortem parkinsonian brain. J Neurochem. 2016 Oct;139 Suppl 1:27-58
˪ Toulorge D, et al
July 5, 2016

Combination of acamprosate and baclofen as a promising therapeutic approach for Parkinson's disease. Scientific Reports (Nature) 2015 Nov 6:16084
˪ Hajj R, et al
November 6, 2015

A meta-analysis of randomized doubleblind clinical trials in CMT1A to assess the change from baseline in CMTNS and ONLS scales after one year of treatment. Orph J Rare Dis. 2015 Jun 13;74
˪ Mandel J, et al
June 13, 2015

Combining two repurposed drugs as a promising approach for Alzheimer’s disease therapy. Scientific Reports (Nature) 2015 Jan 8;7608
˪ Chumakov I, et al
January 8, 2015

An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of Baclofen, Naltrexone and Sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A. Orph J Rare Dis. 2014 Dec 18:199
˪ Attarian S, et al
December 18, 2014

Polytherapy with a combination of three repurposed drugs (PXT3003) down-regulates Pmp22 over-expression and improves myelination, axonal and functional parameters in models of CMT1A neuropathy. Orph J Rare Dis. 2014 Dec 10;201
˪ Chumakov I, et al
December 10, 2014